(Total Views: 73)
Posted On: 09/10/2025 3:32:18 PM
Post# of 66
NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl
Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted by revenue of $1.29 million, up 50.87% year over year, and cash reserves of $6.9 million. The company said the strong balance sheet supports the advancement of AVERSA(TM) Fentanyl, its lead product candidate, which has a Type C FDA meeting scheduled for Sept. 18. Nutriband emphasized that the NDA for AVERSA Fentanyl will rely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required. If approved, the patch could become the first and only abuse-deterrent transdermal fentanyl product globally, with peak annual sales estimated between $80 million and $200 million. AVERSA Buprenorphine, the company’s second program, is projected to reach peak annual sales of up to $130 million. Nutriband continues to grow revenue through its Pocono Pharma contract manufacturing subsidiary, which contributed to the record first half.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted by revenue of $1.29 million, up 50.87% year over year, and cash reserves of $6.9 million. The company said the strong balance sheet supports the advancement of AVERSA(TM) Fentanyl, its lead product candidate, which has a Type C FDA meeting scheduled for Sept. 18. Nutriband emphasized that the NDA for AVERSA Fentanyl will rely on data from a single Phase 1 Human Abuse Potential study, with no Phase 2 or Phase 3 trials required. If approved, the patch could become the first and only abuse-deterrent transdermal fentanyl product globally, with peak annual sales estimated between $80 million and $200 million. AVERSA Buprenorphine, the company’s second program, is projected to reach peak annual sales of up to $130 million. Nutriband continues to grow revenue through its Pocono Pharma contract manufacturing subsidiary, which contributed to the record first half.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://nnw.fm/NTRB
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
